Abstract 683
Background
The American Joint Committee on Cancer 8th Edition (AJCC 8) for oral cavity squamous cell carcinoma (OCSCC) incorporates depth of invasion (DOI) into the pathologic tumor classification (pT) and pathologic extranodal extension (pENE) into the pathologic nodal classification (pN). We sought to evaluate the incidence and prognostic importance of stage migration as a result of these changes on the AJCC 8 staging system.
Methods
From the National Cancer Database, cohorts were identified from patients with OCSCC undergoing definitive surgery between 2004-2013 for pT (n = 7,184), pN (n = 13,627), and pathologic Stage (pStage; n = 5,580) analysis.
Results
DOI and pENE were prognostic in all groups except AJCC 7 pN3. Upstaging was seen in 12.4% of patients for pT classification, 13.3% for pN classification, and 24.8% for overall pathologic stage grouping. Notably, upstaging led to similar or improved five-year overall survival (5-YR OS) for every AJCC 8 pT/N classification except pStage IVB. AJCC 7 pT1 tumors upstaged to AJCC 8 pT3 tumors had improved overall survival compared to the remainder of the pT3 group (71.7% vs 43.7%, respectively, P < 0.0001). A multivariable analysis of up-staged pT3N0 patients demonstrated a reduced risk of death with receipt of PORT (HR 0.56, 95% CI 0.33-0.95, P = 0.03).
Conclusions
Upstaging is common in AJCC 8, and upstaged tumors demonstrate improved survival; these factors that should be kept in mind when interpreting data using the new staging system. Postoperative radiotherapy may reduce death in newly upstaged pT3N0 patients, and further study is needed in this area.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yale School of Medicine.
Funding
Research reported in this publication was supported by the National Institute on Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number T35DK104689 (NCJL). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This publication was made possible by the Yale School of Medicine Medical Student Fellowship (NCJL).
Disclosure
B. Burtness: Honoraria (self), Research grant / Funding (institution): Advaxis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self): IDDI; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy: Celgene; Advisory / Consultancy: Genentech. All other authors have declared no conflicts of interest.
Resources from the same session
1802 - Evaluation of the anti-tumor efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent
Presenter: Kristin Hicks
Session: Poster Display session 3
Resources:
Abstract
3190 - GI101, a novel triple-targeting bispecific CD80-IgG4-IL2variant fusion protein, elicits synergistic anti-tumor effects in preclinical models
Presenter: Jae Chan Park
Session: Poster Display session 3
Resources:
Abstract
4062 - Phase 1b, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumors
Presenter: Julius Strauss
Session: Poster Display session 3
Resources:
Abstract
5777 - THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)
Presenter: Marcos Milla
Session: Poster Display session 3
Resources:
Abstract
5047 - A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
Presenter: Alessandra Curioni
Session: Poster Display session 3
Resources:
Abstract
1679 - HPV16 E6-specific TCR-T armored with checkpoint blockade in the treatment of cervical cancer
Presenter: Paul Bryson
Session: Poster Display session 3
Resources:
Abstract
1133 - the Mutant Neoantigen Specific T Cell Is a Personalized Immunotherapy in Refractory Solid Tumor
Presenter: Qi Song
Session: Poster Display session 3
Resources:
Abstract
3338 - NY-ESO-1 and LAGE1A –an emerging target for cell therapies in solid tumours
Presenter: Ioanna Eleftheriadou
Session: Poster Display session 3
Resources:
Abstract
3089 - Targeting myeloid-derived suppressor cells and T cells: combination treatment with MTL-CEBPA and PD-1 antibody in a mouse syngeneic CT26 model
Presenter: Mikael Sodergren
Session: Poster Display session 3
Resources:
Abstract
5991 - Master Checkpoint Cbl-b Inhibition: Anti-tumor Efficacy in a Murine Colorectal Cancer Model Following siRNA-based Cell Therapy
Presenter: Kathrin Thell
Session: Poster Display session 3
Resources:
Abstract